In Vitro Pharmacodynamic Parameters of Sordarin Derivatives in Comparison with Those of Marketed Compounds against <i>Pneumocystis carinii</i> Isolated from Rats

Pablo Avilés(GlaxoSmithKline (Spain)), Domingo Gargallo‐Viola(GlaxoSmithKline (United Kingdom)), L. Dujardin(Institut Pasteur de Lille), Esperanza Herreros(GlaxoSmithKline (Spain)), Antonio Martı́nez(Hospital Universitario de Móstoles), Eduardo Dei‐Cas(Inserm), El Moukhtar Aliouat(Inserm)
Antimicrobial Agents and Chemotherapy
May 1, 2000
Cited by 35


Related Papers